Copyright
©The Author(s) 2023.
World J Diabetes. Mar 15, 2023; 14(3): 209-221
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.209
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.209
Figure 4 miR-124 protected pancreatic B cell function by targeting EZH2.
A and B: The relative expression levels of EZH2 mRNA and protein were downregulated by si-EZH2 in high glucose (HG)-induced Min6 cells detected by real-time quantitative polymerase chain reaction and Western blot; C: miR-124 inhibitor promoted the proliferation ability of HG-induced Min6 cells by targeting EZH2; D: miR-124 inhibitor promoted the transition from the G0/G1 phase to the S phase at the cell cycle by targeting EZH2; E: miR-124 inhibitor suppressed the apoptosis of HG-induced Min6 cells by targeting EZH2; F: miR-124 inhibitor increased the secretion of insulin in HG-induced Min6 cells by targeting EZH2. aP < 0.05, vs miR-124 inhibitor + si-NC group. NC: Normal control; BC: Blank control; HG: High glucose.
- Citation: Duan XK, Sun YX, Wang HY, Xu YY, Fan SZ, Tian JY, Yu Y, Zhao YY, Jiang YL. miR-124 is upregulated in diabetic mice and inhibits proliferation and promotes apoptosis of high-glucose-induced β-cells by targeting EZH2. World J Diabetes 2023; 14(3): 209-221
- URL: https://www.wjgnet.com/1948-9358/full/v14/i3/209.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i3.209